US OptionsDetailed Quotes

LXEO241220P5000

Watchlist

0.05
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

Lexeo Therapeutics Stock Discussion

Jaguar8

Nov 13 08:36

NEWS ER

$Lexeo Therapeutics (LXEO.US)$
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints
Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling...

Jaguar8

Apr 22 06:31

$Lexeo Therapeutics (LXEO.US)$
NEWS
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Moomoo AI

Dec 11, 2023 06:44

Lexeo's CEO acknowledged significant progress made in 2023, credited to the successful IPO. He anticipates more clinical data from cardiovascular and Alzheimer's disease programs in 2024.

Press Release: Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

FiReBiTriXiE

Nov 30, 2023 22:34

Looks promising here🤔

$Lexeo Therapeutics (LXEO.US)$

No comment yet